Antidepressants for prevention of severe COVID-19, Long COVID and outlook for other viral diseases.

Journal: Frontiers in medicine

Volume: 11

Issue: 

Year of Publication: 

Affiliated Institutions:  Department of Mental Health, Evangelisches Krankenhaus Castrop-Rauxel, Academic Teaching Hospital of the University of Duisburg/Essen, Castrop-Rauxel, Germany. Department of Psychiatry, Psychotherapy and Preventive Medicine, LWL University Hospital, Ruhr University Bochum, Bochum, Germany. Department of Psychiatry and Psychotherapy, University Hospital Cologne, Cologne, Germany.

Abstract summary 

Authors & Co-authors:  Bonnet Juckel Kuhn

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Hoertel N, Sánchez-Rico M, Cougoule C, Gulbins E, Kornhuber J, Carpinteiro A, et al. . Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms. Mol Psychiatry. (2021) 26:7098–9. 10.1038/s41380-021-01254-3
Authors :  3
Identifiers
Doi : 1305184
SSN : 2296-858X
Study Population
Male,Female
Mesh Terms
Other Terms
COVID-19;Long COVID;PACS;Post COVID;antidepressants;prevention;resilience
Study Design
Study Approach
Country of Study
Publication Country
Switzerland